Presented at EASD in Milan, the shot kills fat cells instead of shrinking them. UAB's Timothy Garvey calls the early results remarkable, though not yet peer reviewed.
Recap by typeshit. Full story at LADbible.
Researchers are studying whether GLP-1 drugs, which act on mood, appetite and reward pathways, could help with depression, addiction and binge eating.
A retrospective cohort checks whether retinal disease started or worsened more in established users than in people never on either drug, plus a regional NAION review.
24:34
An animated explainer walking through what semaglutide does in the body, from appetite signals in the brain to digestion and blood sugar control.
A CHEST 2026 records analysis of roughly 2 million patients found 1.4% versus 2.3% at one year. The authors say it shows an association, not proof the drugs caused it.
Experts say holding on to weight loss after quitting a GLP-1 is possible and walk through the habits they recommend for the transition.
A fresh warning points to more people ending up in hospital after taking peptides that aren't approved. Tap through for who issued it.
Loading…